Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10016


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining carboplatin, temozolomide, and filgrastim in treating patients who have newly diagnosed or recurrent high-grade glioma.


Study summary:

OBJECTIVES: - Determine the response rate in patients with newly diagnosed high-grade glioma treated with temozolomide, carboplatin, and filgrastim (G-CSF). - Determine the toxicity of this treatment regimen in these patients. - Determine the rate of tumor progression in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients are stratified according to disease category (glioblastoma multiforme vs anaplastic astrocytoma vs several other high-grade mixed gliomas). Patients receive carboplatin IV over 4 hours on days 1-2; oral temozolomide every 12 hours on days 1-5; and filgrastim (G-CSF) subcutaneously or IV daily starting no earlier than day 7 and continuing until blood counts recover. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 102-222 (17-37 per each of 6 strata) will be accrued for this study within 4 years.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed newly diagnosed glioblastoma multiforme or anaplastic astrocytoma - Residual tumor on postoperative MRI - Bidimensionally measurable disease PATIENT CHARACTERISTICS: Age: - Under 65 Performance status: - Karnofsky or Lansky 70-100% OR - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,000/mm^3 - Hemoglobin at least 8 g/dL (transfusion allowed) - Platelet count greater than 100,000/mm^3 Hepatic: - Bilirubin less than 1.5 times upper limit of normal (ULN) - SGPT no greater than 3 times ULN Renal: - Age 5 years and under: Creatinine less than 1.2 mg/dL - Age over 5 to 10 years: Creatinine less than 1.5 mg/dL - Age over 10 to 15 years: Creatinine less than 1.8 mg/dL - Age over 15 years: Creatinine less than 2.4 mg/dL Cardiovascular: - No myocardial infarction within the past 6 months Other: - No other concurrent serious medical condition that would preclude study - Able to tolerate oral medications - No prior malignancy for which patient received prior chemotherapy or spinal irradiation - No history of severe allergic reaction to platinum-containing compounds - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 72 hours since prior filgrastim (G-CSF) Chemotherapy: - No prior chemotherapy - No other concurrent chemotherapy Endocrine therapy: - Concurrent steroids for tumor-related cerebral edema allowed - No concurrent corticosteroids for solely antiemetic purposes Radiotherapy: - No prior or concurrent radiotherapy Surgery: - Recovered from prior surgery - No concurrent surgery


NCT ID:

NCT00006263


Primary Contact:

Study Chair
Jonathan L. Finlay, MB, ChB
New York University School of Medicine


Backup Contact:

N/A


Location Contact:

New York, New York 10016
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.